Skip to main content
Premium Trial:

Request an Annual Quote

J&J Seeks Authorization

Johnson & Johnson is seeking an Emergency Use Authorization for its SARS-CoV-2 vaccine from the US Food and Drug Administration, CNN reports.

J&J announced last week that its adenovirus-vector SARS-CoV-2 vaccine — which is offered in a one-dose regimen — has a 66 percent efficacy rate in preventing moderate-to-severe COVID-19. The company's findings, though, indicated that the candidate vaccine may be less effective against the viral strain identified in South Africa.

CNN notes that the FDA has scheduled a meeting for later this month of its Vaccines and Related Biological Products Advisory Committee, which will examine the company's vaccine data and make a recommendation. If the FDA is to issue an EUA for J&J's vaccine, it would not then come until the end of the month, CNN adds.

"Adding a third vaccine to the mix would add both supply and flexibility to the struggling US efforts to vaccinate the population," CNN says, adding that J&J's vaccine, in addition to being given as a single dose, and can be stored for months at refrigerator temperatures.

The FDA has previously authorized SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.